BioCentury | Jan 15, 2020
Financial News

Jan. 14 Financial Quick Takes: Schrödinger proposes NASDAQ IPO; plus Mirati, Blackstone, Orexia, Jasper, seqWell

Schrödinger seeking NASDAQ listing Computational physics and drug discovery company Schrödinger Inc. proposed to raise up to $100 million in an IPO on NASDAQ. The company’s largest shareholders are the Bill and Melinda Gates Foundation...
BioCentury | Jul 18, 2019
Financial News

Medicxi’s new €400M fund unites early, late stage investing

Medicxi’s newly closed third fund, its largest ever, will depart from the VC’s prior strategy by consolidating early and late stage investing into a single vehicle. Medicxi III will deploy €400 million ($451.2 million) across...
BioCentury | Feb 9, 2019
Company News

Emerging company roundup: HiberCell, Orexia, TamRx

At least five new biotechs launched this week to develop therapies spanning rare sleep disorders to cancer immunotherapy, while several other emerging companies are moving closer to key inflection points. Of the five newcos, HiberCell...
BioCentury | Feb 8, 2019
Finance

Medicxi’s orexin dream deal

Sleep disorder spinouts Orexia Ltd. and Inexia Ltd. were created to marry Medicxi’s keen interest in agonizing orexin and Heptares Therapeutics Ltd.’s desire to find creative ways to fund its pipeline. Medicxi will invest up...
BioCentury | Feb 7, 2019
Company News

Heptares, Medicxi spin out narcolepsy companies

The Heptares Therapeutics Ltd. unit of Sosei Group Corp. (Tokyo:4565) partnered with life sciences VC Medicxi Ventures to spin out two asset-centric newcos, Orexia Ltd. and Inexia Ltd., to develop preclinical orexin agonists to treat...
BioCentury | Feb 4, 2019
Company News

Heptares, Medicxi spin out narcolepsy companies

The Heptares Therapeutics Ltd. unit of Sosei Group Corp. (Tokyo:4565) partnered with life sciences VC Medicxi Ventures to spin out two asset-centric newcos, Orexia Ltd. and Inexia Ltd., to develop preclinical orexin agonists to treat...
Items per page:
1 - 6 of 6
BioCentury | Jan 15, 2020
Financial News

Jan. 14 Financial Quick Takes: Schrödinger proposes NASDAQ IPO; plus Mirati, Blackstone, Orexia, Jasper, seqWell

Schrödinger seeking NASDAQ listing Computational physics and drug discovery company Schrödinger Inc. proposed to raise up to $100 million in an IPO on NASDAQ. The company’s largest shareholders are the Bill and Melinda Gates Foundation...
BioCentury | Jul 18, 2019
Financial News

Medicxi’s new €400M fund unites early, late stage investing

Medicxi’s newly closed third fund, its largest ever, will depart from the VC’s prior strategy by consolidating early and late stage investing into a single vehicle. Medicxi III will deploy €400 million ($451.2 million) across...
BioCentury | Feb 9, 2019
Company News

Emerging company roundup: HiberCell, Orexia, TamRx

At least five new biotechs launched this week to develop therapies spanning rare sleep disorders to cancer immunotherapy, while several other emerging companies are moving closer to key inflection points. Of the five newcos, HiberCell...
BioCentury | Feb 8, 2019
Finance

Medicxi’s orexin dream deal

Sleep disorder spinouts Orexia Ltd. and Inexia Ltd. were created to marry Medicxi’s keen interest in agonizing orexin and Heptares Therapeutics Ltd.’s desire to find creative ways to fund its pipeline. Medicxi will invest up...
BioCentury | Feb 7, 2019
Company News

Heptares, Medicxi spin out narcolepsy companies

The Heptares Therapeutics Ltd. unit of Sosei Group Corp. (Tokyo:4565) partnered with life sciences VC Medicxi Ventures to spin out two asset-centric newcos, Orexia Ltd. and Inexia Ltd., to develop preclinical orexin agonists to treat...
BioCentury | Feb 4, 2019
Company News

Heptares, Medicxi spin out narcolepsy companies

The Heptares Therapeutics Ltd. unit of Sosei Group Corp. (Tokyo:4565) partnered with life sciences VC Medicxi Ventures to spin out two asset-centric newcos, Orexia Ltd. and Inexia Ltd., to develop preclinical orexin agonists to treat...
Items per page:
1 - 6 of 6